Aesica invests £3m in high containment facility
Will enable the firm to manufacture potent drugs from May 2011
Aesica estimates that the facility, housed in a purpose-built facility at its Queenborough, Kent site, will be completed by May 2011 and once operational will manufacture potent drugs typically classed as Safebridge category 3. The facility will also include security measures to enable it to produce Schedule II controlled drugs such as opiates.
Suites for granulation, tabletting and blister packing, plus appropriate HVAC and cleaning facilities will be built in the high containment unit. It will be separate from the rest of the company’s facilities to prevent cross-contamination.
Adam Sims, Aesica’s commercial director, said: ‘Our service offering and capability is the most advanced in the UK and the addition of the new facility will be of huge benefit to our current clients and indeed all pharmaceutical companies who require potent drug product production.’
Aesica supplies contract development and contract manufacturing services for active pharmaceutical ingredients and formulated products to the world’s leading pharmaceutical companies and emerging biotechnology organisations.
You may also like
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
Cleaning
Micronclean invests £300,000 in state-of-the-art industrial washing machines at its class 4 cleanroom laundry in Skegness
In early summer, Micronclean’s Roman Bank facility completed one of its most ambitious upgrades to date: the installation of two new industrial washers, representing a £300,000 investment in operational efficiency and customer service